CRL Charles River Laboratories International, Inc. Common Stock
NYSE · Life Sciences Tools & Services · SEC EDGAR で表示 ↗ 終値 10月 2, 2026 10-K/10-Q 8月 5, 2026
$290.19
· 52週範囲の%
· 安値より上
· 高値へ
$146.2052週安値
$303.3152週高値
時価総額 (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
収益 (TTM)
$4.00B
あなたのバッジ
52週レンジ
$146–$303
アナリスト評価
BUY
目標株価
$305
P/E
-60.5
ROE
-7.7%
純利益率
-6.0%
バッジストリップは空です。このページ上の任意の指標をピン留めしてください。
CRL 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$290.19
時価総額 (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
収益 (TTM)
$4.00B
ROE (TTM)
-7.7%
負債/自己資本 (MRQ)
0.0
52週レンジ
$146–$303
CRL 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
範囲
バー
バーの粒度は選択した期間に合わせて調整されます。バーの始値/高値/安値/終値を確認するにはチャートにカーソルを合わせてください。
Charles River Laboratories International, Inc. Common Stock について Wikipediaからの企業概要
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
セクターHealthcare
業種Life Sciences Tools & Services
従業員18,300
国US
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益$4.02B2016-12-31 → 2025-12-27
EPS$-2.912016-12-31 → 2025-12-27
フリーキャッシュフロー$518M2016-12-31 → 2025-12-27
純利益率-6.0%2016-12-31 → 2025-12-27
バリュエーションと指標
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
| 指標 | 5年トレンド | CRL | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| P/E (TTM) | -60.55年平均 ≈191.6 | ≈191.6 | · | · | |
| P/S (TTM) | 3.55年平均 ≈3.2 | ≈3.2 | 4.9 | 割安 | |
| 株価純資産倍率 (MRQ) | 4.95年平均 ≈4.1 | ≈4.1 | 3.6 | 適正価格 | |
| EV / EBITDA (EV/EBITDA) | 32.85年平均 ≈16.9 | ≈16.9 | 25.4 | 割安 | |
| 株価FCF倍率 (TTM) | 37.45年平均 ≈28.8 | ≈28.8 | · | · | |
| 株価収益率（P/CF） (TTM) | 23.85年平均 ≈17.3 | ≈17.3 | 26.2 | 割安 | |
| EV / Revenue (EV/売上高) | 3.55年平均 ≈3.1 | ≈3.1 | · | · | |
| EV / FCF (EV/FCF) | 27.15年平均 ≈28.3 | ≈28.3 | · | · | |
| 株価純資産倍率（P/TB） (MRQ) | 5.4 | · | · | · |
同業他社の中央値は、指標ごとに標準化された基準で計算されており、この銘柄に表示されているTTM/MRQ基準と常に一致するとは限りません。
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
| 指標 | 5年トレンド | CRL | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 営業利益率 (TTM) | 2.3%5年平均 ≈10.8% | ≈10.8% | 12.1% | 同水準 | |
| EBITDAマージン (TTM) | 9.7%5年平均 ≈19.2% | ≈19.2% | 14.8% | トップクラス | |
| Pretax Margin (税引前利益率) | -2.5%5年平均 ≈8.6% | ≈8.6% | 12.4% | 弱い | |
| 純利益率 (TTM) | -6.0%5年平均 ≈6.3% | ≈6.3% | 10.8% | 弱い | |
| ROA (TTM) | -3.2%5年平均 ≈3.4% | ≈3.4% | 2.0% | 弱い | |
| ROE (TTM) | -7.7%5年平均 ≈9.0% | ≈9.0% | 3.3% | 弱い | |
| ROIC | 1.1%5年平均 ≈10.7% | ≈10.7% | 3.0% | 弱い |
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
| 指標 | 5年トレンド | CRL | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 負債資本倍率 (MRQ) | 0.05年平均 ≈0.0 | ≈0.0 | 0.1 | 低負債 | |
| 流動比率 (MRQ) | 1.35年平均 ≈1.4 | ≈1.4 | 1.8 | 低流動性 | |
| Quick Ratio (クイックレシオ) | 0.85年平均 ≈0.9 | ≈0.9 | 1.2 | 低流動性 |
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
| 指標 | 5年トレンド | CRL | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Revenue YoY (収益（前年比）) | -0.85%5年平均 ≈6.9% | ≈6.9% | · | · | |
| Revenue CAGR 3Y (収益（3年CAGR）) | 0.33%5年平均 ≈5.7% | ≈5.7% | · | · | |
| Revenue CAGR 5Y (収益（5年CAGR）) | 6.6% | · | · | · | |
| EPS YoY | -97.8%5年平均 ≈-17.6% | ≈-17.6% | · | · | |
| Net Income YoY (純利益（前年比）) | -95.3%5年平均 ≈-16.5% | ≈-16.5% | · | · | |
| EPS CAGR 3Y (EPS年平均成長率 3年) | -70.3% | · | · | · | |
| Net Income CAGR 3Y (純利益年平均成長率 3年) | -61.6% | · | · | · |
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
| 指標 | 5年トレンド | CRL | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Asset Turnover (総資産回転率) | 0.55年平均 ≈0.5 | ≈0.5 | 0.5 | 同水準 | |
| Receivables Turnover (売掛金回転率) | 5.65年平均 ≈5.5 | ≈5.5 | 5.6 | 同水準 | |
| Revenue / Employee (年間売上高 ÷ 従業員数（yfinanceの報告ヘッドカウント）。派生値 — SEC-XBRLの保存概念ではありません。) | ≈$219.4K | · | · | · |
バリュエーション · ≈ 5年平均 · 業界中央値 · 中央値に対する評価
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
8.9%
次回決算
11月 03, 2026
| 期間 | レポート | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|---|
| 2026年6月30日 | 8月 12, 2026 | $3.02 | $2.76 | 9.2% |
| 2026年3月31日 | $2.06 | $1.96 | 5.0% | |
| 2025年12月31日 | $2.39 | $2.37 | 0.98% | |
| 2025年9月30日 | $2.43 | $2.36 | 2.9% | |
| 2025年6月30日 | $3.12 | $2.52 | 23.7% | |
| 2025年3月31日 | $2.34 | $2.10 | 11.4% |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
貸借対照表
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
キャッシュフロー
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
収益性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
流動性と支払能力
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
効率性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
1株あたり
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.30 | $67.69 | $70.06 | $58.42 | $50.21 | $42.49 | $33.40 | $27.33 | $22.05 | $17.67 | $15.70 | $14.20 | |
| Revenue / Share | $81.01 | $78.45 | $80.26 | $77.50 | $68.84 | $57.77 | $52.75 | $46.23 | $38.25 | $35.06 | · | · | |
| Cash Flow / Share | $14.88 | $14.23 | $13.29 | $12.08 | $14.79 | $10.80 | $9.68 | $9.00 | $6.55 | $6.26 | · | · | |
| Cash / Share | $4.34 | $3.81 | $5.39 | $4.59 | $4.78 | $4.59 | $4.86 | $4.05 | $3.46 | $2.48 | $2.53 | $3.38 | |
| EPS (TTM) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 |
成長率
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM）
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
損益計算書
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | · | 49,213,000 | 49,149,000 | 50,677,000 | · | 51,394,000 | 51,551,000 | 51,437,000 | · | 51,283,000 | 51,097,000 | · | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | · | 49,426,000 | 49,316,000 | 50,853,000 | · | 51,583,000 | 51,846,000 | 51,842,000 | · | 51,607,000 | 51,428,000 | · | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
貸借対照表
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
キャッシュフロー
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
収益性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
流動性と支払能力
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
効率性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
1株あたり
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $59.50 | $61.05 | · | $69.20 | $68.14 | $65.04 | · | $73.97 | $72.13 | $70.67 | · | $64.45 | · | · | $51.63 | |
| Revenue / Share | $20.91 | $20.34 | · | $20.33 | $20.93 | $19.35 | · | $19.58 | $19.79 | $19.51 | · | $19.89 | $20.02 | · | $19.29 | |
| Cash Flow / Share | · | $0.84 | · | · | · | $3.38 | · | · | · | $2.51 | · | · | $2.13 | · | · | |
| Cash / Share | $4.02 | $3.98 | · | $4.21 | $3.72 | $4.67 | · | $4.11 | $3.47 | $6.35 | · | $3.06 | · | · | $3.81 | |
| EPS (TTM) | $-4.80 | $-3.71 | · | $-1.51 | $-1.28 | $-0.60 | · | $8.01 | $8.37 | $8.52 | · | $9.25 | $9.68 | · | $8.49 |
バリュエーション（TTM）
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.00B | $4.03B | · | $4.02B | $4.03B | $4.02B | · | $4.06B | $4.08B | $4.11B | · | $4.22B | $4.09B | · | $3.78B | |
| Net Income TTM | $-238M | $-185M | · | $-82M | $-67M | $-25M | · | $424M | $442M | $444M | · | $475M | $496M | · | $436M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | -44.9 | -42.9 | · | -98.4 | -117.2 | -259.2 | · | 24.8 | 24.7 | 31.8 | · | 21.2 | 20.8 | · | 22.1 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | 2.5 | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.6 | 3.3 | · | 2.3 | 2.5 | · | 2.5 | |
| Earnings Yield | -2.2% | -2.3% | · | -1.0% | -0.85% | -0.39% | · | 4.0% | 4.0% | 3.1% | · | 4.7% | 4.8% | · | 4.5% |
最新期間は左側 · null値は・として表示
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
| 指標 | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| 収益 | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| 営業利益率 % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| 純利益 | $-144M | $22M | $475M | $486M | $391M |
| 希薄化後EPS | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| 指標 | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| 負債資本倍率 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 流動比率 | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| クイックレシオ | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
| 指標 | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $518M | $502M | $365M | $295M | $532M |
機関投資家（13F） 607 提出者 · $13.6B合計 · 時点 2026年9月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
保有者
607
保有価値
$13.6B
新規ポジション
74
解消済みポジション
62
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 74 (-17 前期比) | 62 (-19 前期比) | 193 (0 前期比) | 204 (+13 前期比) | +2.8M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1,174,373,670 | 5,887,175 | 8.65% | 株式数 |
| FMR LLC | $961,533,236 | 4,239,752 | 7.09% | 株式数 |
| BlackRock, Inc. | $861,475,349 | 3,798,560 | 6.35% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $714,227,026 | 3,149,288 | 5.26% | 株式数 |
| Invesco Ltd. | $676,919,391 | 2,984,785 | 4.99% | 株式数 |
| HARRIS ASSOCIATES L P | $508,269,048 | 2,241,144 | 3.75% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501,427,927 | 2,210,979 | 3.70% | 株式数 |
| Allspring Global Investments Holdings, LLC | $436,473,035 | 1,905,247 | 3.22% | 株式数 |
| STATE STREET CORP | $422,800,968 | 1,864,284 | 3.12% | 株式数 |
| DIMENSIONAL FUND ADVISORS LP | $373,848,597 | 1,648,450 | 2.76% | 株式数 |
| ARIEL INVESTMENTS, LLC | $341,587,697 | 1,506,185 | 2.52% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $295,598,099 | 1,305,738 | 2.18% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $292,210,525 | 1,288,463 | 2.15% | 株式数 |
| CITADEL ADVISORS LLC | $270,696,771 | 1,193,601 | 1.99% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $265,930,779 | 1,172,586 | 1.96% | 株式数 |
| EARNEST PARTNERS LLC | $254,007,295 | 1,120,011 | 1.87% | 株式数 |
| AMERIPRISE FINANCIAL INC | $199,834,979 | 881,189 | 1.47% | 株式数 |
| NEUBERGER BERMAN GROUP LLC | $195,633,630 | 862,704 | 1.44% | 株式数 |
| SEI INVESTMENTS CO | $184,499,540 | 813,530 | 1.36% | 株式数 |
| MORGAN STANLEY | $181,542,851 | 800,487 | 1.34% | 株式数 |
| Clearbridge Investments, LLC | $177,185,527 | 781,276 | 1.31% | 株式数 |
| COOKE & BIELER LP | $171,369,328 | 755,630 | 1.26% | 株式数 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $157,642,604 | 682,173 | 1.16% | 株式数 |
| VICTORY CAPITAL MANAGEMENT INC | $150,762,735 | 664,768 | 1.11% | 株式数 |
| UBS Group AG | $146,675,752 | 646,747 | 1.08% | 株式数 |
| GOLDMAN SACHS GROUP INC | $145,100,822 | 639,803 | 1.07% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $110,324,717 | 486,462 | 0.81% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $106,061,291 | 467,663 | 0.78% | 株式数 |
| BANK OF MONTREAL /CAN/ | $104,270,783 | 459,768 | 0.77% | 株式数 |
| NORTHERN TRUST CORP | $101,169,205 | 446,092 | 0.75% | 株式数 |
| Gotham Asset Management, LLC | $98,233,181 | 433,146 | 0.72% | 株式数 |
| Amundi | $93,528,650 | 412,402 | 0.69% | 株式数 |
| NORGES BANK | $83,921,372 | 370,040 | 0.62% | 株式数 |
| MARSHALL WACE, LLP | $77,787,835 | 342,995 | 0.57% | 株式数 |
| Iron Triangle Partners LP | $75,748,141 | 379,728 | 0.56% | 株式数 |
| CITIGROUP INC | $71,714,853 | 316,217 | 0.53% | 株式数 |
| BNP PARIBAS FINANCIAL MARKETS | $69,108,583 | 304,725 | 0.51% | 株式数 |
| Bank of New York Mellon Corp | $69,054,385 | 304,486 | 0.51% | 株式数 |
| Boston Trust Walden Corp | $65,523,486 | 288,917 | 0.48% | 株式数 |
| JPMORGAN CHASE & CO | $65,085,033 | 286,317 | 0.48% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $64,615,913 | 374,585 | 0.48% | 株式数 |
| SNYDER CAPITAL MANAGEMENT L P | $63,899,443 | 281,756 | 0.47% | 株式数 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63,174,169 | 278,558 | 0.47% | 株式数 |
| DEUTSCHE BANK AG\ | $62,723,084 | 276,569 | 0.46% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $61,384,115 | 270,665 | 0.45% | 株式数 |
| PRIMECAP MANAGEMENT CO/CA/ | $60,523,448 | 266,870 | 0.45% | 株式数 |
| RAYMOND JAMES FINANCIAL INC | $58,234,910 | 256,779 | 0.43% | 株式数 |
| Meridiem Capital Partners LP | $56,012,367 | 246,979 | 0.41% | 株式数 |
| Alyeska Investment Group, L.P. | $53,295,650 | 235,000 | 0.39% | 株式数 |
| LOOMIS SAYLES & CO L P | $50,725,593 | 223,668 | 0.37% | 株式数 |
アクティビストおよび5%超のオーナー 6保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 提出書類 | 2011年8月4日 | · | 初回提出 | · | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 提出書類 | 2011年2月9日 | · | 初回提出 | · | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 提出書類 | 2010年12月7日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2010年6月16日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2010年6月7日 | · | 初回提出 | 受動的投資 | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 2010年5月5日 | · | 初回提出 | 取締役会キャンペーン | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
企業インサイダー 57 人のインサイダー · 23人の役員 · 29人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Birgit Girshick | Chief Executive Officer | 2026年8月19日 G | 35,485 | 0 | 1 | $-1,819,350 |
| Glenn Coleman | EVP & Chief Financial Officer | 2026年9月30日 P | 27,762 | 1 | 0 | $2,974 |
| Flavia Pease | Corporate Executive VP & CFO | 2025年5月31日 F | 17,297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 2022年3月3日 M | 25,819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 2018年7月24日 M | 17,155 | 0 | 0 | $0 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | 2026年8月19日 M | 4,807 | 0 | 3 | $-2,965,466 |
| Mark Mintz | EVP, Chief Information Officer | 2026年5月31日 F | 9,546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 2024年11月7日 G | 23,337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 2020年6月1日 A | 3,171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 2020年5月29日 A | 224,478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 2016年10月1日 F | 5,599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 2016年3月2日 S | 11,034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 2015年2月25日 M | 14,094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 2010年8月11日 F | 74,390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 2010年2月26日 A | 31,897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 2007年8月11日 F | 37,109 | 0 | 0 | $0 |
| David J Elliott | Officer | 2007年6月29日 M | 11,750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 2007年5月1日 A | 6,262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 2007年4月2日 A | 11,500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 2007年4月2日 F | 12,713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 2007年2月23日 A | 12,710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 2006年2月27日 S | 16,134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 2004年12月23日 M | 8,000 | 0 | 0 | $0 |
| James C Foster | 取締役 | 2026年8月25日 M | 31,596 | 0 | 3 | $-34,844,875 |
| Nancy C Andrews | 取締役 | 2026年8月18日 M | 1,438 | 0 | 1 | $-163,443 |
| Steven Barg | 取締役 | 2026年6月2日 A | 3,287 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | 取締役 | 2026年5月8日 A | 4,563 | 0 | 0 | $0 |
| George Llado | 取締役 | 2026年5月8日 A | 6,702 | 0 | 0 | $0 |
| Abraham Ceesay | 取締役 | 2026年5月8日 A | 2,384 | 0 | 0 | $0 |
| Mark J Enyedy | 取締役 | 2026年5月8日 A | 2,384 | 0 | 0 | $0 |
| Paul W Graves | 取締役 | 2026年5月8日 A | 2,384 | 0 | 0 | $0 |
| Craig B. Thompson | 取締役 | 2026年5月8日 A | 3,851 | 0 | 0 | $0 |
| Martin Mackay | 取締役 | 2026年5月8日 A | 17,137 | 0 | 0 | $0 |
| Virginia M Wilson | 取締役 | 2026年5月8日 A | 6,349 | 0 | 0 | $0 |
| George Massaro | 取締役 | 2025年5月15日 S | 5,575 | 0 | 0 | $0 |
| Richard F Wallman | 取締役 | 2024年11月7日 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | 取締役 | 2024年5月13日 A | 7,894 | 0 | 0 | $0 |
| Robert J Bertolini | 取締役 | 2024年5月13日 A | 32,802 | 0 | 0 | $0 |
| Richard C Reese | 取締役 | 2023年5月15日 A | 65,541 | 0 | 0 | $0 |
| George M Milne JR | 取締役 | 2021年5月7日 A | 29,079 | 0 | 0 | $0 |
| Stephen D Chubb | 取締役 | 2021年2月23日 M | 40,529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | 取締役 | 2019年5月22日 A | 3,886 | 0 | 0 | $0 |
| William Waltrip | 取締役 | 2012年12月5日 S | 21,830 | 0 | 0 | $0 |
| Samuel O Thier MD | 取締役 | 2012年5月9日 A | 18,230 | 0 | 0 | $0 |
| Douglas E Rogers | 取締役 | 2010年5月7日 A | 12,859 | 0 | 0 | $0 |
| Nancy T Chang | 取締役 | 2010年5月7日 A | 31,010 | 0 | 0 | $0 |
| Linda Mcgoldrick | 取締役 | 2006年2月13日 A | · | 0 | 0 | $0 |
| Walter S Nimmo | 取締役 | 2005年2月25日 S | 149,447 | 0 | 0 | $0 |
| John Urquhart | 取締役 | 2005年2月17日 A | 11,738 | 0 | 0 | $0 |
| Louise S Mccrary | 取締役 | 2005年2月17日 A | · | 0 | 0 | $0 |
| Robert Cawthorn | 取締役 | 2004年6月2日 G | 278,600 | 0 | 0 | $0 |
| Joseph W Laplume | · | 2026年8月10日 G | 31,041 | 1 | 1 | $-61,124 |
| Victoria L Creamer | · | 2026年8月6日 M | 30,051 | 0 | 1 | $-1,083,030 |
| Michael Gunnar Knell | · | 2026年8月6日 M | 11,852 | 0 | 9 | $-1,730,250 |
| Thomas F Ackerman | · | 2016年2月29日 F | 111,346 | 0 | 0 | $0 |
| Dennis R Shaughnessy | · | 2004年11月29日 G | 35,511 | 0 | 0 | $0 |
| Michael F Ankcorn | · | 2004年11月4日 S | 0 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
ETF保有状況 108のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| EPSB · Harbor ETF Trust | 2.15% | 443 NS | 2026年7月31日 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 2.00% | 20,123 SH | 2026年10月2日 | 日次 |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.71% | 5,092 NS | 2026年7月31日 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.70% | 51,688 SH | 2026年10月2日 | 日次 |
| EPSV · Harbor ETF Trust | 1.59% | 415 NS | 2026年7月31日 | N-PORT |
| EPMV · Harbor ETF Trust | 1.44% | 291 NS | 2026年7月31日 | N-PORT |
| ALTL · Pacer Funds Trust | 1.09% | 4,303 NS | 2026年7月31日 | N-PORT |
| IBB · iShares Trust | 0.96% | 363,741 SH | 2026年9月11日 | 日次 |
| LSEQ · Harbor ETF Trust | 0.93% | 614 NS | 2026年7月31日 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0.74% | 2,375 NS | 2026年7月31日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.66% | 259 NS | 2026年7月31日 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0.66% | 22,191 SH | 2026年10月2日 | 日次 |
| PDP · Invesco Exchange-Traded Fund Trust | 0.66% | 33,984 SH | 2026年10月2日 | 日次 |
| PALC · Pacer Funds Trust | 0.61% | 5,509 NS | 2026年7月31日 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.49% | 12,141 NS | 2026年7月31日 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.45% | 6,439 NS | 2026年7月31日 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0.42% | 24,876 SH | 2026年10月2日 | 日次 |
| FFSM · FIDELITY COVINGTON TRUST | 0.40% | 25,814 NS | 2026年7月31日 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.34% | 209,615 NS | 2026年7月31日 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.28% | 7,783 NS | 2026年7月31日 | N-PORT |
| ESML · iShares Trust | 0.24% | 25,082 SH | 2026年9月11日 | 日次 |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.24% | 20,898 NS | 2026年7月31日 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.24% | 25,378 NS | 2026年7月31日 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.23% | 13,626 NS | 2026年7月31日 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0.23% | 701,498 SH | 2026年8月19日 | 日次 |
| DFAS · Dimensional ETF Trust | 0.22% | 147,648 NS | 2026年7月31日 | N-PORT |
| IYH · iShares Trust | 0.22% | 28,670 SH | 2026年9月11日 | 日次 |
| RSP · Invesco Exchange-Traded Fund Trust | 0.21% | 701,283 SH | 2026年10月2日 | 日次 |
| SMMD · iShares Trust | 0.19% | 26,152 SH | 2026年9月11日 | 日次 |
| IXJ · iShares Trust | 0.17% | 25,598 SH | 2026年9月11日 | 日次 |
| FHLC · FIDELITY COVINGTON TRUST | 0.17% | 23,486 NS | 2026年7月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.16% | 148,331 SH | 2026年8月19日 | 日次 |
| REVS · Columbia ETF Trust I | 0.15% | 2,111 NS | 2026年7月31日 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.15% | 3,646 NS | 2026年7月31日 | N-PORT |
| WSML · iShares Trust | 0.14% | 6,080 SH | 2026年9月11日 | 日次 |
| IWS · iShares Trust | 0.13% | 73,404 SH | 2026年9月11日 | 日次 |
| VB · VANGUARD INDEX FUNDS | 0.13% | 1,102,914 SH | 2026年8月19日 | 日次 |
| CURE · Direxion Shares ETF Trust | 0.13% | 947 NS | 2026年7月31日 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.12% | 42,976 NS | 2026年7月31日 | N-PORT |
| IEUS · iShares Trust | 0.10% | 5,579 SH | 2026年9月11日 | 日次 |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.10% | 2,769 SH | 2026年10月2日 | 日次 |
| IWR · iShares Trust | 0.10% | 200,615 SH | 2026年9月11日 | 日次 |
| RECS · Columbia ETF Trust I | 0.10% | 23,999 NS | 2026年7月31日 | N-PORT |
| XOEF · iShares Trust | 0.07% | 61 SH | 2026年9月11日 | 日次 |
| DFUV · Dimensional ETF Trust | 0.06% | 41,352 NS | 2026年7月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.06% | 1,302 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.05% | 106,991 NS | 2026年7月31日 | N-PORT |
| IVE · iShares Trust | 0.04% | 79,930 SH | 2026年9月11日 | 日次 |
| IUSV · iShares Trust | 0.04% | 42,675 SH | 2026年9月11日 | 日次 |
| SCZ · iShares Trust | 0.04% | 171,786 SH | 2026年9月11日 | 日次 |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 174,824 SH | 2026年8月19日 | 日次 |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.04% | 11,139 SH | 2026年8月19日 | 日次 |
| DCOR · Dimensional ETF Trust | 0.04% | 5,545 NS | 2026年7月31日 | N-PORT |
| IWD · iShares Trust | 0.04% | 108,791 SH | 2026年9月11日 | 日次 |
| CHRI · Global X Funds | 0.03% | 11 NS | 2026年7月31日 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 29,579 SH | 2026年8月19日 | 日次 |
| TOPC · iShares Trust | 0.03% | 32 SH | 2026年9月11日 | 日次 |
| PRF · Invesco Exchange-Traded Fund Trust | 0.03% | 9,073 SH | 2026年10月2日 | 日次 |
| DFSU · Dimensional ETF Trust | 0.02% | 2,431 NS | 2026年7月31日 | N-PORT |
| XVV · iShares Trust | 0.02% | 576 SH | 2026年9月11日 | 日次 |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.02% | 1,258 SH | 2026年10月2日 | 日次 |
| PBP · Invesco Exchange-Traded Fund Trust | 0.02% | 287 SH | 2026年10月2日 | 日次 |
| EGLE · Global X Funds | 0.02% | 2 NS | 2026年7月31日 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.02% | 7,022 SH | 2026年10月2日 | 日次 |
| IVV · iShares Trust | 0.02% | 607,129 SH | 2026年9月11日 | 日次 |
| VOO · VANGUARD INDEX FUNDS | 0.02% | 1,250,774 SH | 2026年8月19日 | 日次 |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 1,530,468 SH | 2026年8月19日 | 日次 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 8,168 SH | 2026年8月19日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 4,112 SH | 2026年8月19日 | 日次 |
| ESGV · VANGUARD WORLD FUND | 0.02% | 11,106 SH | 2026年8月19日 | 日次 |
| IWV · iShares Trust | 0.02% | 14,165 SH | 2026年9月11日 | 日次 |
| IWB · iShares Trust | 0.02% | 33,863 SH | 2026年9月11日 | 日次 |
| XRMI · Global X Funds | 0.02% | 41 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.02% | 9,979 NS | 2026年7月31日 | N-PORT |
| XYLD · Global X Funds | 0.02% | 2,566 NS | 2026年7月31日 | N-PORT |
| IYY · iShares Trust | 0.02% | 2,018 SH | 2026年9月11日 | 日次 |
| ITOT · iShares Trust | 0.02% | 63,582 SH | 2026年9月11日 | 日次 |
| PTLC · Pacer Funds Trust | 0.02% | 2,492 NS | 2026年7月31日 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0.02% | 38 SH | 2026年10月2日 | 日次 |
| TILT · FlexShares Trust | 0.02% | 1,620 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.02% | 14,645 NS | 2026年7月31日 | N-PORT |
| XYLG · Global X Funds | 0.02% | 45 NS | 2026年7月31日 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.02% | 182 NS | 2026年7月31日 | N-PORT |
| QDPL · Pacer Funds Trust | 0.02% | 1,141 NS | 2026年7月31日 | N-PORT |
| XTR · Global X Funds | 0.01% | 3 NS | 2026年7月31日 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.01% | 332 NS | 2026年7月31日 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.01% | 3,766 NS | 2026年7月31日 | N-PORT |
| IEUR · iShares Trust | 0.01% | 37,473 SH | 2026年9月11日 | 日次 |
| XCLR · Global X Funds | 0.01% | 2 NS | 2026年7月31日 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.01% | 1,973 SH | 2026年10月2日 | 日次 |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 110,946 SH | 2026年8月19日 | 日次 |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 77,796 SH | 2026年8月19日 | 日次 |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.01% | 447,656 SH | 2026年8月19日 | 日次 |
| IDEV · iShares Trust | 0.01% | 52,174 SH | 2026年9月11日 | 日次 |
| IEFA · iShares Trust | 0.00% | 272,340 SH | 2026年9月11日 | 日次 |
| NEAR · iShares U.S. ETF Trust | 0.00% | 140,000 SH | 2026年9月9日 | 日次 |
| DFLV · Dimensional ETF Trust | 0.00% | 377 NS | 2026年7月31日 | N-PORT |
| IXUS · iShares Trust | 0.00% | 22,623 SH | 2026年9月11日 | 日次 |
| VXUS · VANGUARD STAR FUNDS | 0.00% | 664,961 SH | 2026年8月19日 | 日次 |
| VSGX · VANGUARD WORLD FUND | 0.00% | 8,805 SH | 2026年8月19日 | 日次 |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | · | · | 2026年7月15日 | 日次 |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 日次 |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 日次 |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 日次 |
| VGMS · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 日次 |
| ISCB · iShares Trust | · | 2,146 SH | 2026年9月11日 | 日次 |
| ISCV · iShares Trust | · | 10,576 SH | 2026年9月11日 | 日次 |
| SMLF · iShares Trust | · | 18,703 SH | 2026年9月11日 | 日次 |
CRL アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
レーティング · 23 アナリスト
買い
中央値ターゲット
$322.00
+11.0%
6 26.1%
強い買い
11 47.8%
買い
6 26.1%
保有
0 0.0%
売り
0 0.0%
強い売り
12ヶ月目標株価
15 アナリスト · 2026-10-02平均値ターゲット $305.00 +5.1%
現在
現在価格 $290.19
安値$145.00
平均値$305.00
高値$357.00
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
FY基準、価格は各社の直近年度末終値。
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
| TECH | $11.03B | 60.9 | -0.38% | 15.0% | 9.0% | 65.8% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | · |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
| BIO | · | · | · | · | · | · |
最新ニュース この会社に言及した最近の見出し
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
重視する指標を選択してください — 上記の「財務諸表」の任意の行の横にある「+」をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
出典：SEC 10-Q 提出日 8月 5, 2026